Research Interests Overview
The Cancer Research UK funded Clinical Trials & Statistics Unit (ICR-CTSU) provides the scientific leadership and operational management to develop, conduct and report high quality, innovative randomised trials, with integrated translational and psychosocial research.
The aims of the research are to continue to develop, conduct and report high quality trials, and associated research, of scientific importance and which will impact directly on clinical practice within the NHS and internationally.
Dr Emma Hall currently leads on the following Clinical Trials:
Urological Cancer Clinical Trials
CHHiP
Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer
PIVOTAL
A randomised phase II trial of Prostate and pelvIs versus prOstaTe Alone treatment for Locally advanced prostate cancer.
ProSTART
A Pilot Study for a Phase III Clinical Trial in Patients with Favourable Risk Prostate Cancer Comparing Active Surveillance Therapy Against Radical Treatment
Penile TPF
A Phase II Trial of docetaxel, cisplatin & 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis
BC2001
A randomised phase III study of radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer.
Intercontinental
An international phase III randomised trial comparing intermittent versus continuous androgen suppression for patients with prostate-specific-antigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer.
LopeRA
A randomised controlled trial of laparoscopic, open and robot assisted prostatectomy as treatment for organ-confined prostate cancer
111 Trial
The 111 trial is a single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT).
BOXIT
This trial is a randomised phase III multi-centre double-blind placebo-controlled clinical trial. The primary objective is to determine if the addition of the oral COX-2 inhibitor celecoxib to standard therapy is more effective in terms of disease recurrence at 3 years compared to standard therapy alone for the treatment of superficial TCC of the bladder in intermediate and high risk patients.
SPARE
Randomised trial of Selective bladder Preservation Against Radical Excision (cystectomy) in muscle invasive T2/T3 transitional cell carcinoma of the bladder - feasibility study.
Head & Neck Cancer Clinical Trials
PARSPORT
A Phase III multi-centre randomised controlled trial of parotid sparing IMRT in patients with head and neck cancer.
ART DECO
A phase III multi-centre randomised controlled trial to determine the potential of dose escalated IMRT to improve locoregional failure free rate (LRFFR) and laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancers, without increasing the incidence of severe acute and late toxicities to unacceptable levels.
COSTAR
COchlear Sparing Therapy And conventional Radiation - a phase III multi-centre randomised controlled trial designed to demonstrate a difference in the proportion of patients suffering sensori-neural hearing loss of at least 10dB in bone conduction at 4000 Hz.
Urology and Head and Neck Trials Team
Read more about the Dr Hall's teams who are undertaking trials of systemic therapies, radiotherapy and surgical techniques.
